Abstract:Successful development of treatments for non-alcoholic fatty liver disease and its progressive form, non-alcoholic steatohepatitis (NASH), has been challenging. Because NASH and fibrosis lead to progression towards cirrhosis and clinical outcomes, approaches have either sought to attenuate metabolic dysregulation and cell injury, or directly target the inflammation and fibrosis that ensue. Targets for reducing the activation of inflammatory cascades include nuclear receptor agonists (e.g. resmetirom, lanifibranor, obeticholic acid), modulators of lipotoxicity (e.g. aramchol, acetyl-CoA carboxylase inhibitors) or modification of genetic variants (e.g. PNPLA3 gene silencing). Extrahepatic inflammatory signals from the circulation, adipose tissue or gut are targets of hormonal agonists (semaglutide, tirzepatide, FGF19/FGF21 analogues), microbiota or lifestyle interventions. Stress signals and hepatocyte death activate immune responses, engaging innate (macrophages, innate lymphocyte populations) and adaptive (auto-aggressive T cells) mechanisms. Therapies have also been developed to blunt immune cell activation, recruitment (chemokine receptor inhibitors), and responses (e.g. galectin-3 inhibitors, anti-platelet drugs). The disease-driving pathways of NASH converge to elicit fibrosis, which is reversible. The activation of hepatic stellate cells into matrix-producing myofibroblasts can be inhibited by antagonising soluble factors (e.g. integrins, cytokines), cellular crosstalk (e.g. with macrophages), and agonising nuclear receptor signalling. In advanced fibrosis, cell therapy with restorative macrophages or reprogrammed (CAR) T cells may accelerate repair through hepatic stellate cell deactivation or killing, or by enhancing matrix degradation. Heterogeneity of disease - either due to genetics or divergent disease drivers - is an obstacle to defining effective drugs for all patients with NASH that will be overcome incrementally.

Tumor Necrosis Factor-Α Signaling in Nonalcoholic Steatohepatitis and Targeted Therapies

Terf2ip Deficiency Accelerates Non-Alcoholic Steatohepatitis Through Regulating Lipophagy and Fatty Acid Oxidation Via Sirt1/AMPK Pathway

Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis

The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

Tumor Necrosis Factor-Alpha Accelerates Apoptosis of Steatotic Hepatocytes from A Murine Model of Non-Alcoholic Fatty Liver Disease

Treating inflammation to combat non-alcoholic fatty liver disease

Current, emerging, and potential therapies for non-alcoholic steatohepatitis

Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis

NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications

Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives

Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Hepatocyte TNF Receptor-Associated Factor 6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lysine 6-Linked Polyubiquitination of Apoptosis Signal-Regulating Kinase 1

Targeting hepatic macrophages for non-alcoholic fatty liver disease therapy

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions

Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice

Tnf-Alpha-Induce Protein 8-Like 1 Inhibits Hepatic Steatosis, Inflammation, And Fibrosis By Suppressing Polyubiquitination Of Apoptosis Signal-Regulating Kinase 1

Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies

MicroRNAs and Nonalcoholic Steatohepatitis: A Review